Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Yan, Zi-Xun; Li, Li; Wang, Wen; OuYang, Bin-Shen; Cheng, Shu; Wang, Li; Wu, Wen; Xu, Peng-Peng; Muftuoglu, Muharrem; Hao, Ming; Yang, Su; Zhang, Mu-Chen; Zheng, Zhong; Li, James; Zhao, Wei-Li

doi:10.1158/1078-0432.ccr-19-0101

Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cells represent a novel immunotherapy and are highly effective in treating relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL). How tumor microenvironment influences clinical response to CAR T therapy remains of great interest. Patients a…